Pathophysiology, Epidemiology, and Prevention of Pancreatogenic Diabetes - Administrative Supplement

胰源性糖尿病的病理生理学、流行病学和预防 - 行政补充

• 批准号: 9987256
• 负责人: Mark Goodarzi
• 金额: $ 22.08万
• 依托单位: CEDARS-SINAI MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-28 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9987256
• 关键词: Acute; Administrative Supplement; Adult; Age; Ancillary Study; Childhood; Chronic; Cohort Studies; Collection; Cross-Sectional Studies; Diabetes Mellitus; Diagnosis; Diagnostic; Early Diagnosis; Epidemiology; Etiology; Evaluation; Functional disorder; Future; Goals; Hormones; Infrastructure; Institution; International; Intervention Trial; Malignant Neoplasms; Malignant neoplasm of pancreas; Natural History; Pancreatic Ductal Adenocarcinoma; Pancreatitis; Patient Monitoring; Patients; Pediatrics; Performance; Phenotype; Prevention; Prospective cohort; Recruitment Activity; Recurrence; Relapse; Research Personnel; Resources; Risk; Secondary to; Specimen; Testing; Work; acute pancreatitis; biomarker development; biomarker identification; chronic pancreatitis; cohort; epidemiology study; follow-up; individualized medicine; insight; pediatric patients; prospective; recruit; translational study; working group

This is an application for an administrative supplement for the Cedars-Sinai U01 Center of the Consortium on Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) which is led Drs. Pandol and Goodarzi. There has been significant progress within the CPDPC consortium through the efforts of its working groups and committees. However, there are needs to significantly enhance recruitment and monitoring of patients for the cohort studies of CPDCP to meet national goals. The present application provides for plans and resources needed for the Cedars-Sinai U01 Center of the Consortium to make significant contributions to the required national effort. The main goals of the CPDPC are to establish large prospective cohorts of deeply phenotyped patients, with a robust collection of biospecimens for analysis by clinicians and investigators in the future. The cohort studies have been developed by the working groups of the Consortium and include both adult and pediatric patients with proven chronic pancreatitis, suspected or possible chronic pancreatitis, and acute relapsing pancreatitis. These cohorts INSPPIRE2 (INternational Study Group of Pediatric Pancreatitis: In Search for a CuRE) developed by the (CP-RAP) (Chronic Pancreatitis and Recurrent Acute Pancreatitis) Pediatrics Working Group and PROCEED (PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies) developed by the CP-RAP Adult Working Group are actively recruiting subjects, and these specimens and cohorts form the platform for future studies defining etiology, diagnostic criteria, natural history, prevention of progression, and individualized therapy in chronic and recurrent acute pancreatitis. A large cohort of patients at increased risk of pancreatic cancer, those with new onset diabetes above the age of 50 (the New-Onset Diabetes [NOD] cohort), developed by the Diabetes and Pancreatic Ductal Adenocarcinoma (DM-PDAC) Working Group is now also recruiting through the CPDPC and other collaborating institutions, with comprehensive collection of biospecimens and follow-up to provide the infrastructure for identification of biomarkers of very early stage, pre-symptomatic pancreatic cancer. As this cancer presents late and remains highly lethal, this work may allow strategies for early detection. Finally, a cross-sectional study (Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis [DETECT]) developed by the Type 3c Diabetes Mellitus (T3cDM) Working Group is identifying the hormones dysregulated in for diabetes associated with chronic pancreatitis and pancreatic cancer, to provide insights into mechanisms and diagnostic criteria for these conditions. Each of these working groups are currently also pursuing numerous synergistic ancillary studies, including studies of etiology, diagnostic performance, biomarker development, mechanistic studies, and intervention trials.

这是一份慢性病联盟Cedars-Sinai U 01中心的行政补充申请 胰腺炎，糖尿病和胰腺癌（CPDPC），由Pandol和Goodarzi博士领导。 通过各工作组的努力，《和平与发展纲领》联合体取得了重大进展， 委员会。然而，需要显著加强队列患者的招募和监测 研究CPDCP以实现国家目标。本申请提供了实施本发明所需的计划和资源。 雪松西奈U 01中心的财团作出重大贡献，所需的国家努力。 CPDPC的主要目标是建立大型的深度表型患者前瞻性队列， 收集生物标本，供临床医生和研究人员将来分析。队列研究已经 由联盟的工作组制定，包括成人和儿童患者， 胰腺炎、疑似或可能的慢性胰腺炎和急性复发性胰腺炎。这些队列INSPPIRE 2 （国际儿童胰腺炎研究小组：寻找治愈方法）由（CP-RAP）（慢性 胰腺炎和复发性急性胰腺炎）儿科工作组和PROCEED（前瞻性评价 慢性胰腺炎的流行病学和转化研究） 研究组正在积极招募受试者，这些样本和队列构成了未来研究的平台， 病因学、诊断标准、自然史、预防进展和慢性和 复发性急性胰腺炎胰腺癌风险增加的大型患者队列， 50岁以上的糖尿病（新发糖尿病[NOD]队列），由糖尿病和胰腺癌研究所开发。 导管腺癌（DM-PDAC）工作组现在也通过CPDPC和其他组织招募人员。 合作机构，全面收集生物标本并采取后续行动，以提供基础设施 用于鉴定非常早期阶段、症状前胰腺癌的生物标志物。由于这种癌症晚期出现， 并且仍然是高度致命的，这项工作可能允许早期检测的策略。最后，一项横向研究 混合膳食试验对继发于糖尿病的泛糖尿病的诊断和表征的评价 胰腺癌和慢性胰腺炎[DETECT]）由3c型糖尿病（T3 cDM）发展而来 工作组正在确定与慢性胰腺炎相关的糖尿病的激素失调， 胰腺癌，提供深入了解这些条件的机制和诊断标准。这一切成功都 工作组目前也在进行许多协同辅助研究，包括病因学研究， 诊断性能、生物标志物开发、机制研究和干预试验。